Science & Innovation

Approach

Introducing a New Path to Drug Discovery : Bi-XDC technology empowers currently undruggable molecules and targets, transforming them into druggable entities. Designed to tackle substantial unmet medical needs in cancer and beyond, Bi-XDC offers a promising solution for advancing healthcare.

Platforms

Tag-Display

Target Activated lead Generation Display（Tag-Display）is a versatile technology platform for high-throughput discovery and screening of bi-specific ligand system, which can continuously provide the required bi-ligands.

Bi-XDC

CBP has pioneered a breakthrough cellular targeting technology using multi-targeting ligands to effectively deliver desired drug payload to and into the specific cells.

Bispecific Format

Dual tumor antigen targeting
Retains specificity / affinity
Cover Low Receptor expressions
Broad Indications

Molecular Size / Complexity

Enhanced tissue penetration
Simplified manufacturing process

Safety Profile

Wide therapeutic index
Low immunogenicity profile

World of Bi-XDC

Bi-XDC is a breakthrough molecular-level drug delivery system, where conjugated payload is delivered precisely to specific cells via interaction of two ligands with surface receptors of targeted tumor cells, pioneering a novel therapeutic paradigm in this field. Bi-XDC can deliver various payloads, such as toxin (including tubulin inhibitors, topoisomerase inhibitors), PROTAC, radioisotope, photodynamic therapy, immuno-regulators, NK cell & T cell, etc.

Toxin

Bi-XDC seeks to deliver toxin to cancer cells. These comprise dual ligands targeted to a tumor-specific antigen, a linker, which is selectively cleaved by enzymes upregulated in the tumor microenvironment, and a toxic payload. Bi-XDC is designed to fast enrichment of small-molecule toxins at the tumor cells and clearance in healthy cells and tissues，thereby improving therapeutic window.
Tubulin inhibitor: CBP-1008 CBP-1018
Topoisomerase inhibitor: CBP-1019 CBP-1029 CBP-1039

PROTAC

Targeted protein degradation molecules can degrade previously “undruggable” target proteins through their catalytic mechanism of action. We combine bi-XDC technology and the catalytic approach of targeted protein degradation by taking advantage of our privileged bi-XDC technology and PROTAC’s degradation property, increasing the efficacy vs. tolerability window.
CBP-8088

Radioisotope

Bi-XDC delivers DNA damaging radiation as the tumor killing payload. A non-cleavable linker is necessary to improve the stability and safety of drug in the circulation. To avoid the potential hazards of systemic exposure, dual ligands using small size antibodies and peptides has a higher advantage due to their small size, fast tumor penetration and systemic clearance.
CBP-1023

Immuno-regulators

Immuno-regulators change immune system, including treatments that increase or decrease immune response, so it works more effectively. They can treat various conditions, including cancer and autoimmune diseases. Bi-XDC simultaneously delivers toxins and immuno-regulators to tumor cells and tissues, exerting synergistic effect and anti-tumor mechanism.

Photodynamic Therapy

Photodynamic therapy is a non-invasive or minimally-invasive treatment which applies photosensitizers to create reactive oxygen species exposed to light trigger to destroy cancer cells. Bi-XDC targets tumor cells to deliver photosensitizers, and uses dual targets and directional illumination to achieve multiple targeting and precise treatment.
CBP-1062

NK cell & T cell

CAR-NK/T cell therapy is a modified form of NK/T cells extracted from the human body, which involves the introduction of genetically engineered chimeric antigen receptors through gene transfection technology. Combining Bi-XDC technology with CAR-NK/T can greatly improve target efficiency, overcome design difficulty, and reduce production costs.

Pioneering and developing Bi-targeting XDC technology

Science & Innovation